-
-
SBIR-STTR Success: Charlesson LLC/EYECRO
Macular Degeneration is the leading cause of blindness and vision loss in people over 50 –and with life expectancies well into the 80s, it is estimated that 1 and 3 elderly individuals will have to deal with this degenerative disease. The remedy? Monthly injections (via needle) into the back of the eye, where the disease…
-
Bio Matters: Family influences led eyecro’s executive into scientific research
Rafal Farjo, Ph.D. is chief operating officer of both eyecro and Charlesson, which are involved in research to advance treatments for eye disease such as age-related macular degeneration, diabetic retinopathy and ocular inflammation. Far from resisting his family’s interest in all things STEM — science, technology, engineering and math — Farjo embraced it. “I loved it, and…
-
eyecro co-authors paper in Molecular and Cellular Biology studying mechanisms leading to Diabetic Retinopathy
Serum retinol-binding protein (RBP4) is the sole specific transport protein for retinol in the blood, but it is also an adipokine with retinol-independent, pro-inflammatory activity associated with obesity, insulin resistance, type 2 diabetes, and cardiovascular disease. Here we show that RBP4-Tg mice develop progressive retinal degeneration, characterized by photoreceptor ribbon synapse deficiency and subsequent bipolar…
-
Amarantus Announces the Presentation of Data Showing MANF”s Positive Effect on Retinal Function at Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Amarantus BioScience Holdings, Inc. announced the presentation of positive preclinical data for MANF (mesencephalic-astrocyte-derived neurotrophic factor) in retinitis pigmentosa (RP) at the Association for Research in Vision and Ophthalmology Annual Meeting, being held in Denver, CO. The results from preclinical studies demonstrate that MANF preserves the light-sensing function of photoreceptor cells in a genetic model of…
-
eyecro and NeuMedics announce collaboration to utilize MiDROPS™ technology for the development of NM108
Oklahoma City, OK, and Seattle, WA; (May 4, 2015) – eyecro LLC and NeuMedics Inc., today announced the formation of a collaboration to facilitate development of NM108, a first-in-class small molecule to treat a number of ophthalmic disorders that lead to blindness, including Diabetic Retinopathy. The collaboration grants NeuMedics full access to the MiDROPS™ formulation…
-
eyecro COO Dr. Rafal Farjo to Chair Upcoming Conference
The 6th Ocular Diseases & Drug Discovery Conference is taking place on March 20-21, 2014 in San Diego, CA. The conference continues to offer presentations on novel and innovative therapeutics in ocular drug development and discovery. This forum allows for excellent networking, the exchange of ideas, and sharing of challenges; all with a united common…
-
Partnership Aims to Take Advantage of Preclinical Ophthalmology Developments
Rafal Farjo, PhD, COO of eyecro, told Outsourcing-pharma.com that the “demand for ophthalmology studies is increasing. Many research scientists are uncovering new mechanisms and targets for ophthalmic disease, it is also becoming apparent that there is pathology in common with many other clinical indications. eyecro specializes in ophthalmic studies of preclinical efficacy, pharmacokinetics, toxicology, and…
-
Calvert Labs and eyecro Announce Strategic Partnership in Ocular Research
Scott Township, PA – June 10, 2013 – Calvert Labs and eyecro, two leading providers in early-stage ocular drug research and development, announced today that they have entered into a strategic partnership to expedite preclinical drug development activities. “This partnership will facilitate a seamless transition from the discovery and non-GLP stage of drug development to…
-
eyecro COO Gives Talk at ARVO
“Dr. Rafal Farjo, Chief Operating Officer of eyecro, gives a seminar to Members-in-Training on Transitioning from Academia to a Start-up. At the 2013 Annual meeting of the Association for Research in vision and Ophthalmology in Seattle.”
